Published • loading... • Updated
This innovation helped end the pandemic. Now it’s showing strength against cancer
- On Tuesday, Moderna Inc. and Merck & Co. Inc. shared median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study showing intismeran autogene plus Keytruda reduced recurrence or death risk by 49% versus Keytruda alone.
- Following two- and three-year reports, researchers continued follow-up as the analysis builds on earlier two- and three-year follow-up analyses and supports the fully enrolled INTerpath-001 Phase 3 trial.
- Safety data show the combination's profile remains consistent, with the safety profile of intismeran autogene plus Keytruda matching prior reports, while analysts William Blair and Myles Minter praised the five-year update for its positive maintenance of effect and linked adaptive immune responses to tumor control.
- Sponsors plan wider testing of the combination in lung, bladder and kidney cancers as Moderna Inc.'s financial position faces pressure after falling COVID vaccine demand.
- Moderna and Merck will present further follow-up data at an upcoming medical meeting as two non-small cell lung cancer Phase 3 studies and Phase 2 studies continue enrolling.
Insights by Ground AI
23 Articles
23 Articles
Moderna-Merck Skin Cancer Treatment Shows Long-Term Benefits
·New York, United States
Read Full Article
Coverage Details
Total News Sources23
Leaning Left3Leaning Right3Center8Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 22%
C 57%
R 21%
Factuality
To view factuality data please Upgrade to Premium
